Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
/ 2 items
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Summit Therapeutics' promising lung cancer drug, ivonescimab, shows great results in China but struggles in Western trials, raising questions about its global future and impact on biotech.